



## Trokendi XR<sup>®</sup> (topiramate) – New indication

- On April 5, 2017 [Supernus announced](#) the FDA approval of [Trokendi XR \(topiramate\)](#) extended-release capsules, for the prophylaxis of migraine headache in adults and adolescents 12 years of age and older.
  - The usefulness of Trokendi XR in the acute treatment of migraine headache has not been studied.
- Trokendi XR is also indicated for the following:
  - Treatment of patients  $\geq 6$  years of age as initial monotherapy for partial onset or primary generalized tonic-clonic seizures.
  - Adjunctive therapy in patients  $\geq 6$  years of age with partial onset or primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome.
- The approval of Trokendi XR for the prophylaxis of migraine headache was based on clinical studies involving 937 adults and 103 adolescents randomized to immediate-release topiramate or placebo. Patients treated with immediate-release topiramate had greater reductions in migraine frequency from baseline vs. placebo.
- The most common adverse reactions ( $\geq 5\%$  more frequent than placebo) with Trokendi XR at recommended dosing in adult and adolescent controlled migraine clinical trials were paresthesia, anorexia, decreased weight, difficulty with memory, taste perversion, upper respiratory tract infections, abdominal pain, diarrhea, hypoesthesia, and nausea.
- The recommended total daily dose of Trokendi XR as treatment for migraine prophylaxis is 100 mg orally once daily. Trokendi XR is initiated at 25 mg once daily for the first week, then increased weekly by 25 mg increments to the desired clinical outcome.
- Refer to the Trokendi XR drug label for the recommended doses in other indications.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](http://optum.com).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.